Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance
Open accessThe DOI matches its Crossref record; 67 of the 69 references it cites were found in a registry or an index.
Abstract
Angiopoietin-like protein (ANGPTL)3 regulates plasma lipids by inhibiting LPL and endothelial lipase (EL). ANGPTL3 inactivation lowers LDL-C independently of the classical LDLR-mediated pathway and represents a promising therapeutic approach for individuals with homozygous familial hypercholesterolemia due to LDLR mutations. Yet, how ANGPTL3 regulates LDL-C levels is unknown. Here, we demonstrate in hyperlipidemic humans and mice that ANGPTL3 controls VLDL catabolism upstream of LDL. Using kinetic, lipidomic, and biophysical studies, we show that ANGPTL3 inhibition reduces VLDL-lipid content and size, generating remnant particles that are efficiently removed from the circulation. This suggests that ANGPTL3 inhibition lowers LDL-C by limiting LDL particle production. Mechanistically, we discovered that EL is a key mediator of ANGPTL3's novel pathway. Our experiments revealed that, although dispensable in the presence of LDLR, EL-mediated processing of VLDL becomes critical for LDLR-independent particle clearance. In the absence of EL and LDLR, ANGPTL3 inhibition perturbed VLDL catabolism, promoted accumulation of atypical remnants, and failed to reduce LDL-C. Taken together, we uncover ANGPTL3 at the helm of a novel EL-dependent pathway that lowers LDL-C in the absence of LDLR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1. EL is necessary for the LDLR-independent LDL-C-lowering effect upon ANGPTL3 inhibition. A: Inhibition of ANGPTL3 lowers serum phospholipids in Ldlr−/− mice on chow diet 4 days after ANGPTL3 mAb or control mAb (n = 5 mice per group, 10 mg/kg mAb) (left). Mean ± SEM are shown. P-values are from unpaired two-tailed Student’s t-test. Serum lipid distribution in Ldlr−/− mice showing ANGPTL3 mAb lowers phospholipids across all lipoproteins. Pooled serum [n = 6 mice in control (Ctrl) mAb group; n = 5 mice in ANGPTL3 mAb group] was fractionated by FPLC, and phospholipid levels were measured enzymatically in each fraction (right). B: Serum PLTP activity in Ldlr−/− mice on chow diet 6 days before (baseline) and 7 days after ANGPTL3 mAb or control mAb (n = 6 mice per group, 10 mg/kg mAb). Mean ± SEM are shown. P-values are from two-way ANOVA with Sidak correction posttest relative to control. C: Serum lipid distribution of chow-fed WT (n = 10), Lipg−/− (n = 12), Ldlr−/− (n = 23), and Lipg−/−Ldlr−/− (n = 24) mice (left). Pooled serum from each group of mice was separated by HPLC, and cholesterol levels were measured enzymatically. Ratio showing VLDL and LDL APOB-particle numbers in Ldlr−/− and Lipg−/−Ldlr−/− mice (right). D: Nonfasted serum cholesterol of WT and Lipg−/− mice on chow (baseline), after 2 weeks on HFD (HFD baseline), and 6 days after ANGPTL3 or control mAb dose (25 mg/kg) while on HFD. Mean ± SEM are shown (n = 15 mice in WT Ctrl mAb group, n = 16 mice in all other groups). P-values are from two-way ANOVA with Tukey correction posttest. E: Nonfasted serum lipids of Ldlr−/− and Lipg−/−Ldlr−/− mice on chow diet before (baseline, day −6) and 7 days after ANGPTL3 or control mAb-dose (10 mg/kg). Mean ± SEM are shown (n = 14 mice in each Ldlr−/− group, n = 17 mice in Lipg−/−Ldlr−/− Ctrl mAb group, n = 18 mice in Lipg−/−Ldlr−/− ANGPTL3 mAb group). P-values are from two-way ANOVA with Sidak correction posttest.](https://figures.cochat.ai/paper-figures/6312bc63bec6404bae3183ad5bf2144c/angiopoietin-like-protein-3-governs-ldl-cholesterol-levels-through-endothelial-figure-1.jpg)


![Fig. 4. ANGPTL3 inhibition promotes VLDL processing and clearance. A: Plasma clearance kinetics of [3H]CE-labeled VLDL (left) and LDL (right) isolated from Ldlr−/− or Lipg−/−Ldlr−/− mice and injected into Ldlr−/− mice (VLDL from Ldlr−/−: n = 10 recipient mice; VLDL from Lipg−/−Ldlr−/−: n = 9 recipient mice). B: Plasma clearance kinetics of [3H]CE-labeled VLDL (left) or LDL (right) isolated from Apoe−/− mice after 2 weekly injections of ANGPTL3 mAb or control mAb and injected into Apoe−/− mice (n = 10 mice per group). A, B: The percentage of injected CE-label remaining at each timepoint was determined using the value obtained at 30 s as starting point. Mean ± SEM are shown for each timepoint. P-values from two-way ANOVA with Sidak correction posttest: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001. The half-life was calculated from the decay curve of [3H]CE activity plotted against time. All mice were on chow diet. C, D: NMR analysis of human lipoproteins following ANGPTL3 inhibition with evinacumab (ANGPTL3 mAb). Hyperlipidemic individuals were administered ANGPTL3 mAb or control mAb (phase 1 single ascending dose clinical study) (28), and serum was collected at the indicated timepoints. Mean ± SEM are shown for each timepoint (n = 18 in placebo; n = 10 in 5 mg/kg iv; n = 9 in 10 mg/kg iv; n = 11 in 20 mg/kg iv; n = 12 in 150 mg sc; and n = 9 in 250 mg sc groups). Human VLDL/chylomicron and LDL concentration (C) and particle size analysis by NMR (D). P-values are from two-way ANOVA with Tukey correction posttest: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 relative to placebo (color of asterisks indicates relevant group); #P < 0.0001 regarding all ANGPTL3 mAb groups relative to placebo; &P < 0.0001 regarding all intravenously administered ANGPTL3 mAb groups relative to placebo.](https://figures.cochat.ai/paper-figures/e7e016c17f3546eabd59b703a97b776c/angiopoietin-like-protein-3-governs-ldl-cholesterol-levels-through-endothelial-figure-4.jpg)
![Fig. 5. ANGPTL3 inhibition lowers LDL-C independently of several lipoprotein receptors. A: Nonfasted serum lipids of Ldlr−/− and Sdc1−/−Ldlr−/− mice on chow diet before (baseline, day −6) and 7 days after ANGPTL3 or control mAb-dose (10 mg/kg). Mean ± SEM are shown [n = 7 mice in Sdc1−/−Ldlr−/− control (Ctrl) mAb group, n = 8 mice in all other groups]. P-values are from two-way ANOVA with Sidak correction posttest. HPLC analysis shown at right. B, C: The effect of ANGPTL3 inhibition on serum lipids in ASO-mediated knockdown of Scarb1 and/or Lrp1 in Sdc1−/−Ldlr−/− mice on chow diet. Nonfasted serum was collected from Sdc1−/−Ldlr−/− mice (baseline). Scarb1, Scarb1+Lrp1, or control ASOs (25 mg/kg) were administered twice weekly by subcutaneous injections, for a total of 10 doses. Two once-weekly doses of ANGPTL3 or control mAb (10 mg/kg) were administered after first six doses of ASO (ASO pre-mAb). Seven days after the second mAb dose, serum was collected and livers were harvested (ASO, post-mAb). Mean lipid levels ± SEM are shown in B; HPLC analysis of serum is shown in C (n = 8 mice in all groups except n = 7 in Scarb1+Lrp1 ASO + ANGPTL3 mAb group). P-values are from two-way ANOVA with Sidak correction posttest. D: Hepatic knockdown efficiency upon ASO-mediated knockdown of Scarb1 and/or Lrp1 in Sdc1−/−Ldlr−/− mice, corresponding to the study shown in B and C. Mean ± SEM are shown (n = 8 mice per group except n = 7 mice in Scarb1+Lrp1 ASO + ANGPTL3 mAb group). P-values are from one-way ANOVA with Tukey correction posttest. ****P < 0.0001 for Scarb1 ASO groups or Lrp1+Scarb1 ASO groups relative to control ASO groups.](https://figures.cochat.ai/paper-figures/6bd4c3bf1dc54810b0b887dd47f783df/angiopoietin-like-protein-3-governs-ldl-cholesterol-levels-through-endothelial-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, ANGPTL3 inhibition accelerates triglyceride-rich lipoprotein processing and reduces LDL precursors while enhancing HDL catabolism, accounting for concurrent LDL-C reduction and modest HDL-C decrease (Zhang, 2021; Chen et al., 2024; Adam et al., 2020; Wang et al., 2015; Yasuda et al., 2010; Hooper and Burnett, 2013).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Adam et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“It is of particular interest that, contrary to other lipid-lowering drugs, such as PCSK9 inhibitors,21,22 the lipid lowering effect of ANGPTL3 inhibition by evinacumab seems to be independent of the presence of residual LDLR activity, supporting the data obtained in animal models,6,10 as well as in a pilot clinical trial.9”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Extensive studies in animal models suggest that the LDL-C lowering effect of evinacumab is not dependent on a number of other receptors or ligands, such as apolipoprotein E, LDLR-related protein 1, and syndecan 1, which are known to affect LDL or its precursors,6 and SR-BI.10”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Recent reports of studies in mice suggest that EL is required for ANGPTL3 inhibition to reduce LDL-C levels in absence of a functional LDLR.10,11”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“These studies, in mice lacking both LDLR and EL, support the importance of the ANGPTL3/EL pathway in mediating VLDL remnant particle clearance and LDL-C lowering.10”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [10]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 2×
“Differentially expressed genes were identified by DESeq2 (37) package and significantly perturbed genes were defined with fold changes no less than 1.”
InfluentialThe metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Efficient Bayesian mixed-model analysis increases association power in large cohorts
Loh, P.-R., Tucker, G., Bulik-Sullivan, B. K., Vilhjálmsson, B. J., Finucane, H. K., Salem, R. M., Chasman, D. I., Ridker, P. M., Neale, B. M., Berger, B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3190 · Cited by 1,507 · cited 1×
“The association was tested using BOLT under linear mixed model (30).”
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Piedrahita, J. A., Zhang, S. H., Hagaman, J. R., Oliver, P. M., & Maeda, N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4471 · Cited by 944 · cited 1×
“Apoe mice were from JAX (#002052) (27).”
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · cited 1×
“ANGPTL3 inhibition even operates differently than APOC3 or ANGPTL4 blockade, which also activate LPL and promote TG hydrolysis, however have only minor effects on cholesterol reduction (60-62).”
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754 · cited 4×
“Pharmacological inhibition of ANGPTL3 replicates the phenotype of individuals with ANGPTL3 LOF mutations (6, 7) and lowers plasma lipids in mice, monkeys, and humans (9–11).”
InfluentialSelf-citationKowal, R. C., Herz, J., Goldstein, J. L., Esser, V, & Brown, M. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5810 · Cited by 595
High-throughput engineering of the mouse genome coupled with high-resolution expression analysis
Valenzuela, D. M., Murphy, A. J., Frendewey, D., Gale, N. W., Economides, A. N., Auerbach, W., Poueymirou, W. T., Adams, N. C., Rojas, J., Yasenchak, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt822 · Cited by 584
Self-citationCardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Exome sequencing and characterization of 49,960 individuals in the UK Biobank
Van Hout, C. V., Tachmazidou, I., Backman, J. D., Hoffman, J. D., Liu, D., Pandey, A. K., Gonzaga-Jauregui, C., Khalid, S., Ye, B., Banerjee, N., et al. (2020) · Nature · doi:10.1038/s41586-020-2853-0 · Cited by 561
Self-citationPlasma High-Density Lipoproteins
Tall, A. R., & Small, D. M. (1978) · New England Journal of Medicine · doi:10.1056/nejm197811302992207 · Cited by 499
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Self-citationANGPTL3 deficiency and protection against coronary artery disease
Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467
Plasma lipoproteins: genetic influences and clinical implications
Hegele, R. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2481 · Cited by 462
Murphy, A. J., Macdonald, L. E., Stevens, S., Karow, M., Dore, A. T., Pobursky, K., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 455
Self-citationA novel endothelial-derived lipase that modulates HDL metabolism
Jaye, M., Lynch, K. J., Krawiec, J., Marchadier, D., Maugeais, C., Doan, K., South, V., Amin, D., Perrone, M., & Rader, D. J. (1999) · Nature Genetics · doi:10.1038/7766 · Cited by 427
Jiang, X.-C., Bruce, C., Mar, J., Lin, M., Ji, Y., Francone, O. L., & Tall, A. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5578 · Cited by 394
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
Macdonald, L. E., Karow, M., Stevens, S., Auerbach, W., Poueymirou, W. T., Yasenchak, J., Frendewey, D., Valenzuela, D. M., Giallourakis, C. C., Alt, F. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323896111 · Cited by 391
Self-citationDifferences in plasma cholesteryl ester transfer activity in sixteen vertebrate species
Haa, Y. C., & Barter, P. J. (1982) · Comparative Biochemistry and Physiology Part B: Comparative Biochemistry · doi:10.1016/0305-0491(82)90252-8 · Cited by 365
Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203215200 · Cited by 339
Fujino, T., Asaba, H., Kang, M.-J., Ikeda, Y., Sone, H., Takada, S., Kim, D.-H., Ioka, R. X., Ono, M., Tomoyori, H., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0133792100 · Cited by 336
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323 · cited 2×
“blockade lowers LDL-C independently of LDLR (23, 24), providing a new therapeutic avenue for the treatment of FH (25).”
Self-citationWang, Y., Quagliarini, F., Gusarova, V., Gromada, J., Valenzuela, D. M., Cohen, J. C., & Hobbs, H. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315292110 · Cited by 317 · cited 1×
“Accordingly, inhibition of either ANGPTL3 or ANGPTL8 de-represses LPL and lowers plasma TG (11, 14-16).”
Self-citationEndothelial lipase is a major determinant of HDL level
Ishida, T., Choi, S., Kundu, R. K., Hirata, K.-I., Rubin, E. M., Cooper, A. D., & Quertermous, T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16306 · Cited by 306
Shimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297
Characterization of the lipolytic activity of endothelial lipase
McCoy, M. G., Sun, G.-S., Marchadier, D., Maugeais, C., Glick, J. M., & Rader, D. J. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30466-1 · Cited by 280
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Gordts, P. L. S. M., Nock, R., Son, N.-H., Ramms, B., Lew, I., Gonzales, J. C., Thacker, B. E., Basu, D., Lee, R. G., Mullick, A. E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86610 · Cited by 274 · cited 9×
“To address this, we used ASOs for in vivo knockdown of chow-fed SR-B1/ Scarb1 in Ldlr / mice (34).”
InfluentialGreeve, J., Altkemper, I., Dieterich, J., Greten, H., & Windler, E. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36966-2 · Cited by 274
Ahmad, Z., Banerjee, P., Hamon, S., Chan, K.-C., Bouzelmat, A., Sasiela, W. J., Pordy, R., Mellis, S., Dansky, H., Gipe, D. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039107 · Cited by 246
Self-citationStanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L., & Esko, J. D. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38251 · Cited by 226 · cited 1×
“Probing further, we considered heparan sulfate proteoglycan SDC1, a low-affinity high-capacity remnant receptor capable of binding lipoproteins via EL (48, 49).”
Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression
Barr, J., Caballería, J., Martínez-Arranz, I., Domínguez-Díez, A., Alonso, C., Muntané, J., Pérez-Cormenzana, M., García-Monzón, C., Mayo, R., Martín-Duce, A., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr201223p · Cited by 226
Gusarova, V., Alexa, C. A., Wang, Y., Rafique, A., Kim, J. H., Buckler, D., Mintah, I. J., Shihanian, L. M., Cohen, J. C., Hobbs, H. H., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054890 · Cited by 210
Self-citationEhnholm, C., Shaw, W., Greten, H., & Brown, W. V. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)40996-4 · Cited by 205
ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance
Haller, J. F., Mintah, I. J., Shihanian, L. M., Stevis, P., Buckler, D., Alexa-Braun, C. A., Kleiner, S., Banfi, S., Cohen, J. C., Hobbs, H. H., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m075689 · Cited by 199
Self-citationLoss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans
Edmondson, A. C., Brown, R. J., Kathiresan, S., Cupples, L. A., Demissie, S., Manning, A. K., Jensen, M. K., Rimm, E. B., Wang, J., Rodrigues, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37176 · Cited by 192
Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
Wang, Y., Gusarova, V., Banfi, S., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054882 · Cited by 189
Self-citationANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
Chi, X., Britt, E. C., Shows, H. W., Hjelmaas, A. J., Shetty, S. K., Cushing, E. M., Li, W., Dou, A., Zhang, R., & Davies, B. S. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.014 · Cited by 174
Minicocci, I., Montali, A., Robciuc, M. R., Quagliarini, F., Censi, V., Labbadia, G., Gabiati, C., Pigna, G., Sepe, M. L., Pannozzo, F., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1298 · Cited by 168
Lee, E.-C., Desai, U., Gololobov, G., Hong, S., Feng, X., Yu, X.-C., Gay, J., Wilganowski, N., Gao, C., Du, L.-L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807899200 · Cited by 151
Hepatic ANGPTL3 regulates adipose tissue energy homeostasis
Wang, Y., McNutt, M. C., Banfi, S., Levin, M. G., Holland, W. L., Gusarova, V., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515374112 · Cited by 134
Self-citationDose-Dependent Acceleration of High-Density Lipoprotein Catabolism by Endothelial Lipase
Maugeais, C., Tietge, U. J. F., Broedl, U. C., Marchadier, D., Cain, W., McCoy, M. G., Lund-Katz, S., Glick, J. M., & Rader, D. J. (2003) · Circulation · doi:10.1161/01.cir.0000092889.24713.dc · Cited by 132
Yasuda, T., Ishida, T., & Rader, D. J. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0934 · Cited by 122
Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease
Akyea, R. K., Kai, J., Qureshi, N., Iyen, B., & Weng, S. F. (2019) · Heart · doi:10.1136/heartjnl-2018-314253 · Cited by 119
Enhancing metabolomics research through data mining
Martínez‐Arranz, I., Mayo, R., Pérez-Cormenzana, M., Mincholé, I., Salazar, L., Alonso, C., & Mato, J. M. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.01.019 · Cited by 116
Fuki, I. V., Blanchard, N., Jin, W., Marchadier, D. H. L., Millar, J. S., Glick, J. M., & Rader, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302181200 · Cited by 115
Van Hout, C. V., Tachmazidou, I., Backman, J. D., Hoffman, J. X., Ye, B., Pandey, A. K., Gonzaga-Jauregui, C., Khalid, S., Liu, D., Banerjee, N., et al. (2019) · doi:10.1101/572347 · Cited by 110
Self-citationYen, F. T., Mann, C. J., Guermani, L. M., Hannouche, N. F., Hubert, N., Hornick, C. A., Bordeau, V. N., Agnani, G., & Bihain, B. E. (1994) · Biochemistry · doi:10.1021/bi00171a017 · Cited by 100
Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism
Reyes-Soffer, G., Sztalryd, C., Horenstein, R. B., Holleran, S., Matveyenko, A., Thomas, T., Nandakumar, R., Ngai, C., Karmally, W., Ginsberg, H. N., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311476 · Cited by 97
New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk
Kersten, S. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000600 · Cited by 94
Murray, S., Ittig, D., Koller, E., Berdeja, A., Chappell, A., Prakash, T. P., Norrbom, M., Swayze, E. E., Leumann, C. J., & Seth, P. P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks273 · Cited by 91
Gusarova, V., Banfi, S., Alexa-Braun, C. A., Shihanian, L. M., Mintah, I. J., Lee, J. S., Xin, Y., Su, Q., Kamat, V., Cohen, J. C., et al. (2017) · Endocrinology · doi:10.1210/en.2016-1894 · Cited by 80
Self-citationFoley, E. M., Gordts, P. L. S. M., Stanford, K. I., Gonzales, J. C., Lawrence, R., Stoddard, N., & Esko, J. D. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301637 · Cited by 77 · cited 2×
“Without LDLR, EL activity becomes critical, yet clearance of EL-modified VLDL may involve multiple redundant receptors (47–51).”
Mortimer, B.-C., Beveridge, D. J., Martins, I. J., & Redgrave, T. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28767 · Cited by 74
Ko, K. W. S., Paul, A., Ma, K., Li, L., & Chan, L. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500366-jlr200 · Cited by 71
Endothelial Lipase Promotes the Catabolism of ApoB-Containing Lipoproteins
Broedl, U. C., Maugeais, C., Millar, J. S., Jin, W., Moore, R. E., Fuki, I. V., Marchadier, D., Glick, J. M., & Rader, D. J. (2004) · Circulation Research · doi:10.1161/01.res.0000130657.00222.39 · Cited by 68
Nijstad, N., Wiersma, H., Gautier, T., van der Giet, M., Maugeais, C., & Tietge, U. J. F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807683200 · Cited by 68
Pouwer, M. G., Pieterman, E. J., Worms, N., Keijzer, N., Jukema, J. W., Gromada, J., Gusarova, V., & Princen, H. M. G. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000419 · Cited by 66 · cited 1×
“Consistent with this notion, a recent publication revealed that triple combination treatments of statins and antibodies targeting PCSK9 and ANGPTL3 yielded additive effects on cholesterol and atherosclerosis reductions in mice (59).”
Self-citationEric, F., Elizabeth, L., & Roger, S. (2014) · The Journal of Biomedical Research · doi:10.7555/jbr.28.20140019 · Cited by 61
Romeo, S., Yin, W., Kozlitina, J., Pennacchio, L. A., Boerwinkle, E., Hobbs, H. H., & Cohen, J. C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37118 · Cited by 58
Self-citationHu, L., van der Hoogt, C. C., Espirito Santo, S. M. S., Out, R., Kypreos, K. E., van Vlijmen, B. J. M., Van Berkel, T. J. C., Romijn, J. A., Havekes, L. M., van Dijk, K. W., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800130-jlr200 · Cited by 49
Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State
Tikkanen, E., Minicocci, I., Hällfors, J., Costanzo, A. D., D’Erasmo, L., Poggiogalle, E., Donini, L. M., Würtz, P., Jauhiainen, M., Olkkonen, V. M., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312021 · Cited by 43
Santo, S. M. S. E., Rensen, P. C. N., Goudriaan, J. R., Bensadoun, A., Bovenschen, N., Voshol, P. J., Havekes, L. M., & van Vlijmen, B. J. M. (2005) · Journal of Lipid Research · doi:10.1194/jlr.c500007-jlr200 · Cited by 34
Eisenberg, S., Schurr, D., Goldman, H., & Olivecrona, T. (1978) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(78)90216-3 · Cited by 23
Impact of Endothelial Lipase on Cholesterol Efflux Capacity of Serum and High-density Lipoprotein
Schilcher, I., Kern, S., Hrzenjak, A., Eichmann, T. O., Stojaković, T., Scharnagl, H., Duta-Mare, M., Kratky, D., Marsche, G., & Frank, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-12882-7 · Cited by 21
Advances in treatment of dyslipidaemia
Grundy, S. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.208 · Cited by 14
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“76 The preceding discussion illustrates the difficulty inherent in defining remnants.”
BackgroundEvinacumab in Patients with Refractory Hypercholesterolemia
Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031049 · Cited by 302
Hepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252
“Furthermore, inhibition of ANGPTL3 reduces VLDL lipid content and size in an endothelial lipase-dependent manner [41].”
BackgroundInhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion
Wang, J.-Q., Li, L.-L., Hu, A., Deng, G., Wei, J., Li, Y.-F., Liu, Y.-B., Lu, X.-Y., Qiu, Z.-P., Shi, X.-J., et al. (2022) · Nature · doi:10.1038/s41586-022-05006-3 · Cited by 188
Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00195.2021 · Cited by 154
Metadata
- Authors
- Adam, R. C., Mintah, I. J., Alexa-Braun, C. A., Shihanian, L. M., Lee, J. S., Banerjee, P., Hamon, S. C., Kim, H. I., Cohen, J. C., Hobbs, H. H., Van Hout, C., Gromada, J., Murphy, A. J., Yancopoulos, G. D., Sleeman, M. W., & Gusarova, V.
- Affiliations
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Gusarova, Viktoria
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 61
- Issue
- 9
- Pages
- 1271-1286
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC7469887
- OpenAlex
- W3041635484
- Cited by
- 208
- References
- 69
- Citations by year
- 2026: 34 · 2025: 28 · 2024: 36 · 2023: 29 · 2022: 33 · 2021: 42 · 2020: 6
- FWCI
- 17.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 80 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Heart, Lung, and Blood Institute (P01HL020948)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, endothelial lipase, VLDL clearance, LDL cholesterol, VLDL remnants, hypercholesterolemia, lipoprotein metabolism, lipidomics
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Animals, Female, Humans, Lipase, Cholesterol, LDL, Lipoproteins, VLDL, Male, Receptors, LDL, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.